Cumberland shares Phase 2 ifetroban data showing 5.4% LVEF gain in DMD

Updated FIGHT DMD results presented at the PPMD conference also showed lower cardiac injury biomarkers and no treatment-related serious adverse events through 36 months.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.